Sandoz Group AG (SDZXF)
| Market Cap | 37.98B +40.1% |
| Revenue (ttm) | 11.68B +10.3% |
| Net Income | 646.00M +184.6% |
| EPS | 1.47 +180.8% |
| Shares Out | n/a |
| PE Ratio | 58.79 |
| Forward PE | 20.02 |
| Dividend | 1.01 (1.13%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | 353 |
| Open | 89.26 |
| Previous Close | n/a |
| Day's Range | 89.26 - 89.26 |
| 52-Week Range | 55.50 - 94.55 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. Sandoz Group A... [Read more]
Financial Performance
Financial StatementsNews
Sandoz initiated with a Buy at Erste Group
Erste Group analyst Hans Engel initiated coverage of Sandoz (SDZNY) with a Buy rating. The company’s product pipeline in the biosimilars segment is expanded and new markets will be tapped,…
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initi...
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drug...
Sandoz price target raised to CHF 80 from CHF 75 at JPMorgan
JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 80 from CHF 75 and keeps an Overweight rating on the shares.
Sandoz Shares Climb After Biosimilar Sales Drive Growth
Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.
Sandoz Group AG Earnings Call Transcript: Q2 2026
Strong H1 2026 results driven by biosimilars, with 5% net sales growth and margin expansion. Regulatory milestones, new launches, and a robust pipeline underpin confidence in 2026 guidance and a positive outlook for 2027-2028.
Sandoz Group AG Slides: Q2 2026
Sandoz Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Sandoz Group AG Quarterly report: Q2 2026
Sandoz Group AG has published its Q2 2026 quarterly earnings report on August 5, 2026.
Sandoz Group AG Earnings release: Q2 2026
Sandoz Group AG released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Sandoz results narrowly beat sales expectations
Swiss generic maker Sandoz reported a 9% jump in second quarter net sales on Wednesday, slightly above analyst expectations, as it reaped the benefits of patent expirations in its biosimila...
Sandoz takes steps to resolve U.S. generic medicine pricing litigation
Sandoz (SDZNY) announces several steps to further resolve the US Generic Drug Antitrust Pricing Litigation. Sandoz and its subsidiary Fougera Pharmaceuticals have entered into a settlement agreement t...
Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations
The agreements mean the remaining claims against the Swiss maker of generic drugs in the U.S. generic antitrust litigation are those from individual plaintiffs.
Sandoz agrees $450 mln settlement with 43 US states over antitrust claims
Swiss generic drugmaker Sandoz said on Monday that it has entered into a $450 million settlement agreement with 43 U.S. states and territories to resolve litigations concerning alleged anti-compet...
Generic drug sector seeks policy fixes after Trump tariff threat
The generic drug market still faces structural and purchasing hurdles despite strong U.S. growth, an industry group noted on Wednesday, after President Donald Trump said imported generic medicines w...
Generic drugmaker Sandoz to engage with US after Trump tariff threat
Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufa...
Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide
Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New Drug Applications, ANDAs, for generic versions of tirzepatide. The ANDAs seek approv...
FDA set to review Sandoz's generic GLP-1s
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly.
Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the co...
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two biosimilar insulins, for injection in prefilled pens, are developed by ...
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The firm finds the stock’s valuation “compelling” given Sandoz’s accelerating sales growth th...
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps a Hold rating on the shares.
Sandoz Group AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust biosimilar-driven growth, with net sales up 11% headline and 3% at constant currencies, and biosimilars now 31% of sales. Generics declined due to portfolio pruning and B2B headwinds, but stabilization is expected from Q2. Full-year guidance for mid to high single-digit sales growth and margin expansion is reaffirmed.
Sandoz Group AG Slides: Q1 2026
Sandoz Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Sandoz Group AG Earnings release: Q1 2026
Sandoz Group AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.